PsA Secukinumab XCT Structural Progression Study

NCT03623867 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Psoriatic Arthritis

Interventions

DRUG: Secukinumab
DRUG: Placebo

Sponsor

Chinese University of Hong Kong